Verrica Pharmaceuticals (VRCA)
(Delayed Data from NSDQ)
$2.08 USD
-0.22 (-9.57%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $2.10 +0.02 (0.96%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Price, Consensus and EPS Surprise
VRCA 2.08 -0.22(-9.57%)
Will VRCA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VRCA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VRCA
Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Tops Revenue Estimates
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates
VRCA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates
Other News for VRCA
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
Wall Street Breakfast: The Week Ahead
Catalyst Watch: August Jobs Report, Intel event, Broadcom earnings, and Costco sales
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
Verrica Pharmaceuticals CCO Joe Bonaccorso Resigns, Assumes Consulting Role